.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

EU Perspective: Evolving Topics in Prostate Cancer

EP. 1: M0 Stage Prostate Cancer

November 27th 2018

EP. 2: Radiotherapy for Oligometastatic Prostate Cancer

November 27th 2018

EP. 3: Defining Disease Volume in Metastatic Prostate Cancer

November 27th 2018

EP. 4: Nonmetastatic CRPC: Does It Exist?

November 27th 2018

EP. 5: Biochemical Prostate Cancer Recurrence Post Surgery/RT

November 27th 2018

EP. 6: Bone Health in Prostate Cancer

November 27th 2018

EP. 7: Key Updates: Bone-Targeted Therapy for Metastatic CRPC

November 27th 2018

EP. 8: Effect of Prostate Cancer Therapies on Bone Metabolism

November 27th 2018

EP. 9: ERA 223 and Implications for Clinical Practice

November 27th 2018

EP. 10: Assessment of Bone Health in Prostate Cancer

November 27th 2018

EP. 11: Earlier Detection of Prostate Cancer Bone Metastases

November 27th 2018

EP. 12: Therapeutic Sequencing for CRPC Based on Recent Data

November 27th 2018

EP. 13: Genotyping in Prostate Cancer

November 27th 2018

EP. 14: PARP Inhibitors in Advanced Prostate Cancers

November 27th 2018

EP. 15: Chemotherapy for BRCA-Mutated Prostate Cancer

November 27th 2018